Cytophage Technologies Ltd. (TSXV:CYTO)

Cytophage Technologies Income Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	4.39	3.26	2.99
Research & Development	0.02	0.44	0.44
Operating Expenses	5.42	5.04	4.25
Operating Income	-5.42	-5.04	-4.25
Interest Expense	-0.11	-0.03	-0.02
Interest & Investment Income	0.13	0	-
Other Non Operating Income (Expenses)	0.19	0.45	0.59
EBT Excluding Unusual Items	-5.21	-4.62	-3.68
Other Unusual Items	-2.7	-0.01	-
Pretax Income	-7.91	-4.64	-3.68
Net Income	-7.91	-4.64	-3.68
Net Income to Common	-7.91	-4.64	-3.68
Shares Outstanding (Basic)	50	42	41
Shares Outstanding (Diluted)	50	42	41
Shares Change (YoY)	22.29%	3.74%	-
EPS (Basic)	-0.16	-0.11	-0.09
EPS (Diluted)	-0.16	-0.11	-0.09
Free Cash Flow	-5.85	-3.02	-3.32
Free Cash Flow Per Share	-0.12	-0.07	-0.08
EBITDA	-5.18	-4.74	-4.03
D&A For EBITDA	0.24	0.3	0.22
EBIT	-5.42	-5.04	-4.25

Source: S&P Global Market Intelligence. Standard template. Financial Sources.